EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Update on metformin for osteoarthritis treatment

Ben-Zheng Li, He-Xin Wei, Shu-Zhi Li, Yong-Ze Yang, An-Ren Zhang, Hong-Zhang Guo

Inflammopharmacology · 2025

DOI: 10.1007/s10787-025-01902-y ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Inflammopharmacology, 2025. Verfasst von Ben-Zheng Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: First Clinical Medical College of Gansu, University of Traditional Chinese Medicine, Lanzhou, China. Hauptthemen laut MEDLINE: Metformin, Osteoarthritis, Metabolic Syndrome, Obesity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 84 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteoarthritis (OA) is a prevalent degenerative joint disease among middle-aged and elderly individuals. Metabolic syndrome (Met S), a group of clinical conditions characterized by abnormal metabolic processes, includes obesity as one of its primary risk factors. Recent studies have demonstrated a significant association between metabolic syndrome and osteoarthritis. Metformin, a classical hypoglycemic agent, is commonly prescribed for patients with type 2 diabetes mellitus who do not achieve adequate control through diet and physical activity alone. Metformin has gradually gained attention in the treatment of OA due to its anti-inflammatory, antioxidant, and metabolic function-enhancing properties. This review summarizes the latest research on metformin by examining recent clinical and animal studies, systematically analyzing its mechanisms, and assessing its clinical potential in treating OA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminOsteoarthritisMetabolic SyndromeObesityAnti-Inflammatory AgentsAntioxidantsClinical Studies as TopicHumansAnimalsDisease Models, AnimalSignal TransductionQuality of Life

Stichwörter der Autor:innen

Anti-catabolismAnti-inflammatory effectInflammatory mediatorsMetabolic syndromeMetforminOsteoarthritis

Substanzen

MetforminAnti-Inflammatory AgentsAntioxidants

Autor:innen und Institutionen

  • First Clinical Medical College of Gansu, University of Traditional Chinese Medicine, Lanzhou, China.
  • People's Hospital of Gansu Province, 204 Donggang West Road, Chengguan District, Lanzhou, 730000, China.
  • People's Hospital of Gansu Province, 204 Donggang West Road, Chengguan District, Lanzhou, 730000, China. g_hz@163.com.

Zitieren

APA

Li, B. Z., Wei, H. X., Li, S. Z., Yang, Y. Z., Zhang, A. R., & Guo, H. Z. (2025). Update on metformin for osteoarthritis treatment. Inflammopharmacology. https://doi.org/10.1007/s10787-025-01902-y

Vancouver

Li BZ, Wei HX, Li SZ, Yang YZ, Zhang AR, Guo HZ. Update on metformin for osteoarthritis treatment. Inflammopharmacology. 2025. doi:10.1007/s10787-025-01902-y

BibTeX
@article{Li2025,
  author = {Li, Ben-Zheng and Wei, He-Xin and Li, Shu-Zhi and Yang, Yong-Ze and Zhang, An-Ren and Guo, Hong-Zhang},
  title = {Update on metformin for osteoarthritis treatment},
  journal = {Inflammopharmacology},
  year = {2025},
  doi = {10.1007/s10787-025-01902-y}
}
Kostenlos starten →